Company Overview
Humacyte, Inc. is a biotechnology firm dedicated to the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues designed for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company operates within the broader Healthcare sector and specifically within the Biotechnology industry, positioning itself at the intersection of advanced biological engineering and clinical application. As of the latest reporting period, the company holds a market capitalization of $179.41M and employs a workforce of 218 individuals. The annual revenue generated over the trailing twelve months stands at $1.57M, figures that indicate the company is currently in an early-stage development or commercialization phase where significant capital expenditure is required before achieving widespread market penetration or profitability.
Financial Health
The company reported a revenue of $1.57M for the trailing twelve months, yet simultaneously recorded a net income of $-36,969,000 and an EBITDA of $-97,324,000, revealing a cost structure where operating expenses and research and development costs vastly exceed current revenue streams. This substantial gap between minimal revenue and significant net losses suggests that the company is still in a heavy investment phase, likely funding proprietary technology development and clinical trials rather than generating operational profit. Free cash flow stands at $-74,158,248, indicating that the company is burning cash rapidly and lacks immediate financial flexibility to fund operations without external capital raises or existing cash reserves. The company currently holds $19.49M in cash assets against $50.97M in total debt, creating a net debt position that requires careful management to avoid liquidity constraints. While the debt-to-equity ratio is listed as N/A due to the company's equity dynamics, the absolute debt load relative to cash holdings suggests a leveraged balance sheet typical of pre-revenue biotech firms. The current ratio is 1.62, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate buffer against immediate liquidity crises. Return on Equity is listed as N/A, while Return on Assets is -63.4%, metrics that collectively reveal that management is currently generating negative returns on the capital invested in the firm.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the company's lack of net income, whereas the forward P/E is -1.56, implying that the market is pricing in a continued period of negative earnings or expecting a turnaround before traditional earnings-based valuation becomes applicable. The price-to-book ratio is -27.43, a negative figure that indicates the market capitalization is significantly below the company's book value, often seen in unprofitable firms where assets may not be fully reflected on the balance sheet or where intangible R&D assets dominate. The price-to-sales ratio is 114.20, and the EV/EBITDA is -1.91; these alternative valuation metrics suggest that investors are pricing the stock based on potential future utility and proprietary technology rather than current financial performance or historical profitability. The 52-week high is $3.36 and the 52-week low is $0.70, meaning the current trading price sits at a level that reflects high volatility and significant potential downside risk relative to the recent peak performance. The beta value is 1.93, which indicates that the stock price is expected to fluctuate with significantly higher volatility than the broader market, amplifying both potential gains and losses during periods of market movement.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the fact that the company has not yet established a consistent track record of growth or profitability required to calculate these standard comparative metrics. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue using standard percentage calculations, as both numerator and denominator for growth rates are either negative or unavailable for comparison. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available capital and operational earnings back into its research, development, and clinical trial programs rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies in the early stages of commercialization, prioritizing long-term asset building over short-term shareholder returns. The overall growth and income profile is characterized by a complete absence of current income generation and a reliance on external financing to sustain operations while pursuing future market expansion.